1116570-97-8

Basic information

• Product Name: Carbamic acid, N,N-dimethyl-, 3-[[[(2S)-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]amino]phenyl ester
• Synonyms: LIMKIN14;LIMK IN 14;LIMK-IN-14;LIMK inhibitor-14;LIMK inhibitor 14;MVPARBNSRQJBEM-HNNXBMFYSA-N;CarbaMic acid, N,N-diMethyl-, 3-[[[(2S)-2-Methyl-4-(5-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1-piperazinyl]carbonyl]aMino]phenyl ester
• CAS NO: 1116570-97-8
• Molecular Formula: C22H27N7O3
• Molecular Weight: 437.501
• Mol File: 1116570-97-8.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, N,N-dimethyl-, 3-[[[(2S)-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]amino]phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, N,N-dimethyl-, 3-[[[(2S)-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]amino]phenyl ester(1116570-97-8)
• EPA Substance Registry System: Carbamic acid, N,N-dimethyl-, 3-[[[(2S)-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]amino]phenyl ester(1116570-97-8)

Safety Data

• Hazardous Substances Data: 1116570-97-8(Hazardous Substances Data)

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 1116570-96-7 (S)-5-methyl-4-(3-methylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 19962-04-0 Dimethylcarbaminsaeure-3-aminophenylester 

Downstream Products

• 1116570-96-7 (S)-5-methyl-4-(3-methylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine 
• 19962-04-0 Dimethylcarbaminsaeure-3-aminophenylester 
• 19961-65-0 (3-Dimethylcarbamoyloxy-phenyl)-carbamic acid methyl ester 
• 1116569-68-6 (S)-N-(3-methoxyphenyl)-2-methyl-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazine-1-carboxamide 

Relevant articles and documents

Discovery and development of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of glaucoma

The structure of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma, is disclosed. Previously reported LIM kinase inhibitors suffered from poor aqueous stability due to solvolysis of the central urea. Replacement of the urea with a hindered amide resulted in aqueous stable compounds, and addition of solubilizing groups resulted in a set of compounds with good properties for topical dosing in the eye and good efficacy in a mouse model of ocular hypertension. LX7101 was selected as a clinical candidate from this group based on superior efficacy in lowering intraocular pressure and a good safety profile. LX7101 completed IND enabling studies and was tested in a Phase 1 clinical trial in glaucoma patients, where it showed efficacy in lowering intraocular pressure. (Figure Presented).

Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma

The discovery of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported. These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good selectivity against ROCK. After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels. The compounds also increase outflow facility in a pig eye perfusion assay. These results suggest LIMK2 may be an effective target for treating ocular hypertension and associated glaucoma.

KINASE INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use